Sunday, Dec 1 2024 | Time 22:55 Hrs(IST)
image
Business EconomyPosted at: Nov 8 2024 6:12PM


Granules India receives EIR from US FDA for Unit V Facility

Hyderabad, Nov 8 (UNI) Granules India Limited, a leading pharmaceutical manufacturing company, on Friday announced it has received an Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (FDA) for its Unit V facility located at Jawaharlal Nehru Pharma City (JNPC), in Anakapalli district of Andhra Pradesh.
The inspection was conducted by the US FDA from April 8 to April 12, 2024, the Pharma company said in a release here.
The US FDA inspection classified the facility as "No Action Indicated" (NAI), indicating compliance with current Good Manufacturing Practices (cGMP) standards and confirming that no further regulatory action is required.
This outcome reflects the facility's high standards in the production of Active Pharmaceutical Ingredients (APIs) and Finished Dosages (FDs) for both oncology and non-oncology therapeutic areas.
During the inspection, the FDA conducted a comprehensive Pre-Approval Inspection (PAI) and cGMP audit, which concluded with zero Form 483 observations, underscoring Granules India’s commitment to stringent quality control, regulatory compliance, and operational excellence.
"The successful completion of this US FDA inspection with zero observations and the subsequent receipt of the EIR with NAI status reflects our unwavering commitment to maintaining the highest quality standards in our manufacturing operations," said Dr. Krishna Prasad Chigurupati, Chairman & Managing Director.
Granules India’s Unit V facility plays a pivotal role in the company’s mission to deliver high-quality and accessible pharmaceuticals globally by prioritizing regulatory compliance, operational excellence, and value delivery to stakeholders.
The company remains dedicated to producing top-quality pharmaceutical products that meet global health standards.
UNI KNR CS1811
Please log in to get detailed story.
Tags: #Granules India receives EIR from US FDA for Unit V Facility
More News

Hyderabad: Zetexa, a start-up incubated at T-Hub launches new-age travel technology product 'ZetSIM'

01 Dec 2024 | 7:54 PM

Hyderabad, Dec 1 (UNI)Zetexa, a new-age travel technology start-up incubated at
T-Hub, launched the first of its kind travel technology product 'ZetSIM' in India.

see more..

Five Halder group companies merge into its BSE-listed entity HVL

01 Dec 2024 | 5:33 PM

Kolkata, Dec 1 (UNI) Halder Venture Limited (HVL), the BSE-listed entity of the Halder group and a leader in the rice manufacturing and processing sector in eastern India, has successfully completed its North-South merger with five other group companies, creating a stronger, unified entity.

see more..

Air India Express commences daily flights between Kolkata & Sri Vijaya Puram

01 Dec 2024 | 5:14 PM

Kolkata, Dec 1 (UNI) Air India Express on Sunday inaugurated its daily direct flight between Kolkata and Sri Vijaya Puram (Port Blair), marking a significant milestone for the airline’s network expansion in the region.

see more..

Cabinmate launches 17th Center in Hyderabad

30 Nov 2024 | 7:14 PM

Hyderabad, Nov 30 (UNI) Cabinmate, India’s first and largest corporate reading room and community management company, on Saturday announced that it has launched its 17th Center at King Koti here, in collaboration with Kamineni Hospitals.

see more..

Hyderabad: 117 MoUs signed at TConsult Collaboration Conclave 2024

30 Nov 2024 | 7:05 PM

Hyderabad, Nov 30 (UNI) The TConsult Collaboration Conclave 2024, inaugurated by Telangana IT and Industries Minister Sridhar Babu Duddila, marked a historic milestone with the signing of 117 Memorandums of Understanding (MoUs), aimed at fostering collaboration, innovation, and growth across industries.

see more..
image